Protara Therapeutics’ (NASDAQ:TARA) TARA-002 received FDA rare pediatric disease designation for the treatment of lymphatic malformation. Lymphatic malformations are rare, typically congenital and result in the failure...
Protara Therapeutics’ (NASDAQ:TARA) IV choline chloride received FDA fast track designation for the treatment of intestinal failure-associated liver disease (IFALD). IFALD occurs in patients who have been receiving...
Ladenburg Thalmann initiated coverage of ArTara Therapeutics (NASDAQ:TARA) with a “buy” rating and $45 price target. The stock closed at $28.34 on Jan. 21. ArTara has two late-stage clinical assets in development for...